Cytek Biosciences (CTKB) announced preliminary revenue results for the fourth quarter and full year ended December 31, 2025. Cytek expects total revenue for the full year 2025 to be approximately $201 million. For the fourth quarter, the company projects revenue of approximately $62 million, growth of 8% compared to the fourth quarter of 2024.
Cytek plans to report financial results for the fourth quarter, and to provide 2026 financial guidance during its earnings call expected to be held near the end of February 2026.
In pre-market trading on NasdaqGS, Cytek Biosciences shares are up 9.7 percent to $5.98.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.